177Lu-Ludotadipep (177Lu-FC705) is a 177Lu-labeled analogue of 177Lu-Vipivotide targeting PSMA. In order to increase stability and specificity of the molecule, and to reduce side-effects, albumin was introduced in the structure, creating a so-called second generation of radiolabeled PSMA targeting therapeutics.
177Lu-Ludotadipep completed Phase I in 2022.